Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (int...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | The Lancet Regional Health. Europe |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666776222000643 |
| _version_ | 1818116003410739200 |
|---|---|
| author | Julian Stumpf Jörg Schwöbel Tom Lindner Leona Anders Torsten Siepmann Claudia Karger Jan Hüther Heike Martin Petra Müller Robert Faulhaber-Walter Torsten Langer Holger Schirutschke Thomas Stehr Frank Meistring Annegret Pietzonka Kirsten Anding-Rost Katja Escher Frank Pistrosch Jens Schewe Harald Seidel Kerstin Barnett Thilo Pluntke Simon Cerny Alexander Paliege Ingolf Bast Anne Steglich Florian Gembardt Friederike Kessel Hannah Kröger Patrick Arndt Jan Sradnick Kerstin Frank Anna Klimova René Mauer Xina Grählert Torsten Tonn Christian Hugo |
| author_facet | Julian Stumpf Jörg Schwöbel Tom Lindner Leona Anders Torsten Siepmann Claudia Karger Jan Hüther Heike Martin Petra Müller Robert Faulhaber-Walter Torsten Langer Holger Schirutschke Thomas Stehr Frank Meistring Annegret Pietzonka Kirsten Anding-Rost Katja Escher Frank Pistrosch Jens Schewe Harald Seidel Kerstin Barnett Thilo Pluntke Simon Cerny Alexander Paliege Ingolf Bast Anne Steglich Florian Gembardt Friederike Kessel Hannah Kröger Patrick Arndt Jan Sradnick Kerstin Frank Anna Klimova René Mauer Xina Grählert Torsten Tonn Christian Hugo |
| author_sort | Julian Stumpf |
| collection | DOAJ |
| description | Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 1205 participants including medical personnel (125 MP), dialysis patients (970 DP) and kidney transplant recipients (110 KTR) with seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Six months after vaccination, seroconversion remained positive in 98% of MP, but 91%/87% of DP/KTR (p = 0·005), respectively. Receptor binding domain-IgG (RBD-IgG) antibodies were positive in 98% of MP, but only 68%/57% of DP/KTR (p < 0·001), respectively. Compared to MP, DP and KTR were at risk for a strong IgG or RBD-IgG decline (p < 0·001). Within the DP but not KTR group male gender, peritoneal dialysis, short time on dialysis, BNT162b2mRNA vaccine, immunosuppressive drug use and diabetes mellitus were independent risk factors for a strong decline of IgG or RBD antibodies. The percentage of cellular immunity decline was similar in all groups. Interpretation: Both vulnerable DP and KTR groups are at risk for a strong decline for IgG and RBD antibodies. In KTR, antibody titres peak at a markedly lower level and accelerated antibody decline is mixed with a delayed/increasing IgG, RBD-IgG, or cellular immune response in a 16% fraction of patients. In both populations, immune monitoring should be used for early timing of additional booster vaccinations. Funding: This study was funded by the Else Kröner Fresenius Stiftung, Bad Homburg v. d. H., grant number Fördervertrag EKFS 2021_EKSE.27. |
| first_indexed | 2024-12-11T04:15:36Z |
| format | Article |
| id | doaj.art-93fbef297f324ff2a8226adec54e3a66 |
| institution | Directory Open Access Journal |
| issn | 2666-7762 |
| language | English |
| last_indexed | 2024-12-11T04:15:36Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Europe |
| spelling | doaj.art-93fbef297f324ff2a8226adec54e3a662022-12-22T01:21:16ZengElsevierThe Lancet Regional Health. Europe2666-77622022-06-0117100371Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc studyJulian Stumpf0Jörg Schwöbel1Tom Lindner2Leona Anders3Torsten Siepmann4Claudia Karger5Jan Hüther6Heike Martin7Petra Müller8Robert Faulhaber-Walter9Torsten Langer10Holger Schirutschke11Thomas Stehr12Frank Meistring13Annegret Pietzonka14Kirsten Anding-Rost15Katja Escher16Frank Pistrosch17Jens Schewe18Harald Seidel19Kerstin Barnett20Thilo Pluntke21Simon Cerny22Alexander Paliege23Ingolf Bast24Anne Steglich25Florian Gembardt26Friederike Kessel27Hannah Kröger28Patrick Arndt29Jan Sradnick30Kerstin Frank31Anna Klimova32René Mauer33Xina Grählert34Torsten Tonn35Christian Hugo36Medizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; KfH-Nierenzentrum Dresden, Dresden, GermanyDialysezentrum Chemnitz, Chemnitz, GermanyDivision of Nephrology, University Hospital Leipzig, Leipzig, GermanyDialysepraxis Leipzig, Leipzig, GermanyKfH-Nierenzentrum am Klinikum Chemnitz, Krankenhaus Küchwald, Chemnitz, GermanyKfH-Nierenzentrum am Klinikum St. Georg, Leipzig, GermanyNephrocare GmbH Döbeln, Döbeln, GermanyNephrologisches Zentrum Zwickau, Zwickau, GermanyPHV Dialysezentrum Dresden-Johannstadt, Dresden, GermanyNephrologisches Zentrum Freiberg, Freiberg, GermanyDialysezentrum Annaberg, Annaberg-Buchholz, GermanyPHV Dialysezentrum Dresden Friedrichstadt, Dresden, GermanyKfH-Nierenzentrum Bautzen, Bautzen, GermanyKfH-Nierenzentrum am Städtischen Klinikum Görlitz, Görlitz, GermanyVia medis Nierenzentrum Dresden MVZ GmbH, Dresden, GermanyKfH-Nierenzentrum Bischofswerda, Bischofswerda, GermanyKfH-Gesundheitszentrum Aue, Aue-Bad-Schlema, GermanyNephrologisches Zentrum Hoyerswerda, Hoyerswerda, GermanyDialyse- und Nierenambulanz Sebnitz, Sebnitz, GermanyKfH-Nierenzentrum am Vogtland Krankenhaus Plauen, Plauen, GermanyDialyse Heidenau, Heidenau, GermanyKfH-Nierenzentrum Grimma, Grimma, GermanyELBLAND Dialyse Großenhain, Großenhain, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyDialysepraxis Leipzig, Leipzig, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, GermanyInstitut für Transfusionsmedizin Plauen, DRK-Blutspendedienst Nord-Ost Gemeinnützige GmbH, Plauen, GermanyNational Center for Tumor Diseases (NCT) Partner Site Dresden, Dresden, GermanyFaculty of Medicine Carl Gustav Carus, Institute for Medical Informatics and Biometry (IMB), Technische Universität, Dresden, GermanyCoordinating Centre for Clinical Trials, Dresden, GermanyInstitute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany; Faculty of Medicine Carl Gustav Carus, Transfusion Medicine, Technische Universität, Dresden, GermanyMedizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; KfH-Nierenzentrum Dresden, Dresden, Germany; Corresponding author at: Medizinische Klinik und Poliklinik III, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 1205 participants including medical personnel (125 MP), dialysis patients (970 DP) and kidney transplant recipients (110 KTR) with seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Six months after vaccination, seroconversion remained positive in 98% of MP, but 91%/87% of DP/KTR (p = 0·005), respectively. Receptor binding domain-IgG (RBD-IgG) antibodies were positive in 98% of MP, but only 68%/57% of DP/KTR (p < 0·001), respectively. Compared to MP, DP and KTR were at risk for a strong IgG or RBD-IgG decline (p < 0·001). Within the DP but not KTR group male gender, peritoneal dialysis, short time on dialysis, BNT162b2mRNA vaccine, immunosuppressive drug use and diabetes mellitus were independent risk factors for a strong decline of IgG or RBD antibodies. The percentage of cellular immunity decline was similar in all groups. Interpretation: Both vulnerable DP and KTR groups are at risk for a strong decline for IgG and RBD antibodies. In KTR, antibody titres peak at a markedly lower level and accelerated antibody decline is mixed with a delayed/increasing IgG, RBD-IgG, or cellular immune response in a 16% fraction of patients. In both populations, immune monitoring should be used for early timing of additional booster vaccinations. Funding: This study was funded by the Else Kröner Fresenius Stiftung, Bad Homburg v. d. H., grant number Fördervertrag EKFS 2021_EKSE.27.http://www.sciencedirect.com/science/article/pii/S2666776222000643SARS-CoV-2mRNA vaccinationAntibody fadingMedical personnelDialysis patientsKidney transplant recipients |
| spellingShingle | Julian Stumpf Jörg Schwöbel Tom Lindner Leona Anders Torsten Siepmann Claudia Karger Jan Hüther Heike Martin Petra Müller Robert Faulhaber-Walter Torsten Langer Holger Schirutschke Thomas Stehr Frank Meistring Annegret Pietzonka Kirsten Anding-Rost Katja Escher Frank Pistrosch Jens Schewe Harald Seidel Kerstin Barnett Thilo Pluntke Simon Cerny Alexander Paliege Ingolf Bast Anne Steglich Florian Gembardt Friederike Kessel Hannah Kröger Patrick Arndt Jan Sradnick Kerstin Frank Anna Klimova René Mauer Xina Grählert Torsten Tonn Christian Hugo Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study The Lancet Regional Health. Europe SARS-CoV-2mRNA vaccination Antibody fading Medical personnel Dialysis patients Kidney transplant recipients |
| title | Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study |
| title_full | Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study |
| title_fullStr | Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study |
| title_full_unstemmed | Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study |
| title_short | Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study |
| title_sort | risk of strong antibody decline in dialysis and transplant patients after sars cov 2mrna vaccination six months data from the observational dia vacc study |
| topic | SARS-CoV-2mRNA vaccination Antibody fading Medical personnel Dialysis patients Kidney transplant recipients |
| url | http://www.sciencedirect.com/science/article/pii/S2666776222000643 |
| work_keys_str_mv | AT julianstumpf riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT jorgschwobel riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT tomlindner riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT leonaanders riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT torstensiepmann riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT claudiakarger riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT janhuther riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT heikemartin riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT petramuller riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT robertfaulhaberwalter riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT torstenlanger riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT holgerschirutschke riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT thomasstehr riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT frankmeistring riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT annegretpietzonka riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT kirstenandingrost riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT katjaescher riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT frankpistrosch riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT jensschewe riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT haraldseidel riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT kerstinbarnett riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT thilopluntke riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT simoncerny riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT alexanderpaliege riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT ingolfbast riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT annesteglich riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT floriangembardt riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT friederikekessel riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT hannahkroger riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT patrickarndt riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT jansradnick riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT kerstinfrank riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT annaklimova riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT renemauer riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT xinagrahlert riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT torstentonn riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy AT christianhugo riskofstrongantibodydeclineindialysisandtransplantpatientsaftersarscov2mrnavaccinationsixmonthsdatafromtheobservationaldiavaccstudy |